Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

A new COVID variant is raising questions and capturing the attention of researchers heading into the fall and winter season.

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for ...

New treatment builds on Pfizer’s migraine portfolio to further meet the needs of people living with this debilitating disease ...

Pharmaceutical giant Pfizer (NYSE: PFE) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Pfizer PFE in the ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

We came across a bullish thesis on Pfizer Inc. (PFE) on gurufocus by Akim Guerreiro. In this article we will summarize the ...